Minetto, Paola <br/><br/>
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.  [electronic resource] 

 -  British journal of haematology  02 2019 
 - 457-460 p.  digital 
<br/><br/> Publication Type: Letter 
<br/><br/><label>ISSN: </label>1365-2141 
<br/><br/><label>Standard No.: </label>10.1111/bjh.15106  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Cytarabine--administration & dosage<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Idarubicin--administration & dosage<br/>Leukemia, Myeloid, Acute--blood<br/>Male<br/>Middle Aged<br/>Neoplasm, Residual<br/>Survival Rate<br/>Vidarabine--administration & dosage